Eli Lilly Prices Record $6.75 Billion Bond Sale Amid Scarce Long-Dated Supply
Eli Lilly & Co. has launched its largest-ever U.S. investment-grade corporate bond offering, pricing $6.75 billion across seven tranches. The deal includes a rare 40-year bond—a bold MOVE in today's high-rate environment—priced at 73 basis points over Treasuries. Proceeds will address general corporate needs, including debt reduction for the $35 billion-liability pharmaceutical giant.
The transaction underscores shrinking appetite for long-dated corporate debt. Only 11% of 2024's high-grade issuances carried 30+ year maturities, down from 15% last year, as borrowers balk at locking in elevated yields. Lilly's offering coincided with debt issuances from other blue chips like McDonald's on August 18.
Log in to Reply
Log in to comment your thoughtsComments
Related Articles
|Square
Get the BTCC app to start your crypto journey
Get started today Scan to join our 100M+ users